Researchers at UMass Amherst have developed BacID, a bacteria-based cancer therapy that uses genetically engineered, non-toxic Salmonella to target tumors and deliver therapeutic agents directly into cancer cells. The bacteria, administered intravenously, preferentially colonize tumors and release their drug payload only after being triggered by aspirin.
This precise mechanism minimizes harm to healthy tissue and avoids the severe side effects of conventional treatments like chemotherapy. Preclinical studies have shown significant tumor reduction and long-term immunity in models of high-mortality cancers such as pancreatic and metastatic breast cancer.
Clinical trials are expected to begin in 2027, offering a promising new approach to treating aggressive cancers (no prostate at first but it's a pan-cancer solution).
Cool idea. I just thought of something. Since UMASS is a state government institution then shouldn’t it be able to bring this new drug or procedure to FDA approval without astronomical costs.
I’m pretty sure some pharmaceutical will fund it and get the rights to it and the institutions will get it share. Thus it will cost much more than it should. Just my conical thoughts.
TBH I think about organizing a kind of charity to support at least phase 1 research, but not of a number of projects (for that I already donate to a couple of organizations), something really targeted, and possibly (don't ask me how) a kind of "fast lane" for the people who contributed to the financing...like those perks they use in crowd funding
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Challenges from the Increased Spread of COVID-19